80 related articles for article (PubMed ID: 1609218)
1. [Therapeutic strategy in metastatic renal cancer].
Droz JP; Kramar A; Wibault P; Perrin JJ; Roche A; Escudier B; Missenard G; Court BH
Rev Prat; 1992 May; 42(10):1253-7. PubMed ID: 1609218
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
3. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
Schmitz-Dräger BJ; Jankevicius F; Otto T
Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
[TBL] [Abstract][Full Text] [Related]
5. [Renal cell carcinoma--a current review].
Schmid HP; Szabo J
Praxis (Bern 1994); 1997 May; 86(20):837-43. PubMed ID: 9312811
[TBL] [Abstract][Full Text] [Related]
6. [Metastatic cancer of the kidney. What can be done today?].
Chautard D; Lanson Y
J Urol (Paris); 1988; 94(7):307-16. PubMed ID: 3065413
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
9. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
11. Erythrocyte sedimentation rate as a prognostic factor in renal cell carcinoma.
Hannisdal E; Bostad L; Grøttum KA; Langmark F
Eur J Surg Oncol; 1989 Aug; 15(4):333-6. PubMed ID: 2759251
[TBL] [Abstract][Full Text] [Related]
12. [Management of advanced renal cell carcinoma: surgical treatment of metastasis].
Kinouchi T; Kotake T
Hinyokika Kiyo; 1994 Oct; 40(10):919-24. PubMed ID: 7992709
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma.
Culine S; Bekradda M; Kramar A; Rey A; Escudier B; Droz JP
Cancer; 1998 Dec; 83(12):2548-53. PubMed ID: 9874462
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer.
Kuczyk M; Wegener G; Jonas U
Eur Urol; 2005 Aug; 48(2):252-7. PubMed ID: 15936136
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment of brain metastases from solid tumours.
Cappuzzo F; Mazzoni F; Maestri A; Di Stefano A; Calandri C; Crino L
Forum (Genova); 2000; 10(2):137-48. PubMed ID: 10875975
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
17. [What is the impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma?].
Oya M; Murai M
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1732-7. PubMed ID: 12402422
[TBL] [Abstract][Full Text] [Related]
18. The failure of infarction and/or nephrectomy in stage IV renal cell cancer to influence survival or metastatic regression.
Flanigan RC
Urol Clin North Am; 1987 Nov; 14(4):757-62. PubMed ID: 3314066
[TBL] [Abstract][Full Text] [Related]
19. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
20. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
